SCHEMBL6573022

SCHEMBL6573022

CC(C)S(=O)(=O)NCCc1ccc2cc(OCC#N)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 3/20 0.47
PTGS2 P35354 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
CA5A P35218 2/20 0.37
CA14 Q9ULX7 2/20 0.37
SLC2A1 P11166 2/20 0.37
ALDH1A1 P00352 2/20 0.36
KCNH2 Q12809 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH2 P05091 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6572264 0.86 PTGS2 (0.45) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6563315 0.84 GRIA4 (0.62) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6575364 0.83 PTGS2 (0.57) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6574096 0.83 GRIA4 (0.47) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6763745 0.82 GRIA4 (0.48) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6765787 0.82 GRIA4 (0.46) GRIA4PTGS2SMN1; SMN2CA12CA1
SCHEMBL6763716 0.81 KDM4E (0.46) GRIA4PTGS2ALDH1A1KCNH2KDM4E
SCHEMBL6762646 0.81 GRIA4 (0.52) GRIA4
SCHEMBL6765790 0.78 PPARG (0.59)
SCHEMBL6572128 0.77 GRIA4 (0.54) GRIA4PTGS2SMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 GRIA4 9/4885PTGS2 959/4885SMN1; SMN2 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.